Topical Itraconazole in Treating Patients With Basal Cell Cancer

Skin Basal Cell Carcinoma Clinical Trial

Official title:
A Case Study of the Effects of Topical Itraconazole on Pharmacodynamic Modulation of Hedgehog Target Gene Expression in Basal Cell Carcinomas in Patients

Status Completed

Clinical Trial Summary

This phase 0 trial studies how well itraconazole gel works in treating patients with basal cell cancer. Itraconazole gel may help to treat basal cell tumors in patients.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To determine if 12 weeks of topical itraconazole gel reduces basal cell carcinoma (BCC) biomarkers (Gli1, the target gene of the Hedgehog pathway).

SECONDARY OBJECTIVES:

I. To determine if topical itraconazole gel will decrease BCC size.

OUTLINE:

Patients apply itraconazole topically twice daily (BID) and placebo topically BID for 12 weeks.

After completion of study treatment, patients are followed up for up to 14 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02735356
Study type	Interventional
Source	Stanford University
Contact
Status	Completed
Phase	Early Phase 1
Start date	May 5, 2016
Completion date	October 10, 2017

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02978625` - Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	Phase 2
Completed	`NCT03180528` - Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer	Phase 2
Completed	`NCT02690948` - Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer	Phase 1/Phase 2
Completed	`NCT02579551` - Effectiveness of Narrow Margins in Patients With Low-Risk Basal Cell Carcinoma Undergoing Surgery	N/A
Withdrawn	`NCT02699723` - Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer	Early Phase 1